Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Altace Will Provide "Stable" Growth Platform For Three Years, King Says

This article was originally published in The Pink Sheet Daily

Executive Summary

King plans to tap the ACE inhibitor's market potential through expanded indications and inclusion of ramipril on hospital discharge protocols, Corporate Head of Commercial Operations Andrzejewski says. The company is targeting the second half of 2005 for NDA filings in pediatric hypertension and chronic kidney disease.

You may also be interested in...



Cobalt's Altace Generic Gets FDA Approval, 180 Days Of Exclusivity

King and Cobalt appear to be in settlement talks over ongoing patent litigation in Boston federal court.

Cobalt's Altace Generic Gets FDA Approval, 180 Days Of Exclusivity

King and Cobalt appear to be in settlement talks over ongoing patent litigation in Boston federal court.

Altace Will See Challenge From Generic ACE Inhibitors, Not Class Labeling, King Says

Increased attention to benefits of antihypertensives will help Altace and the entire class, King says. “We just have to fight the...battle” on differentiation, CEO Markison says.

Related Content

Topics

UsernamePublicRestriction

Register

PS061962

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel